Navigation Links
Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents
Date:8/26/2013

istration—positive cardiovascular outcomes data emerges as a primary preference for the GLP-1 analogues. Agents targeting these unmet needs should also help to address payer demands for downstream cost-savings, thus encouraging budget holders at all levels to think beyond the price tag as competition heightens among type 2 diabetes drug classes.    

However, the report also finds that as manufacturers strive for optimal pricing and reimbursement terms amid stringent HTA demands, they must be careful not to price themselves out of the market if they want to secure maximum uptake of their brands. Price must be carefully balanced with uptake potential for optimal return on investment.

"One quarter of surveyed GPs in Germany do not currently prescribe GLP-1 analogues to more than half of their eligible type 2 diabetes patients due to the constraints of their indicative prescribing budgets, while around two thirds of survey respondents in Spain report that their ability to prescribe DPP-IV inhibitors and GLP-1 analogues is at least somewhat impacted by recently increased patient copay," said Decision Resources Senior Director Janie Cox, Ph.D. "As the EU5 countries continue to feel the force of the economic crisis, industry is challenged with maximizing profitability at competitive rather than premium prices."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sec
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
3. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
4. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
5. Optimization of Comparative Efficacy Trials
6. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
11. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Morria Biopharmaceuticals Plc, a,biopharmaceutical company focused ... announced that it has obtained regulatory,approval from ... to initiate,a Phase II study of MRX-4 ... The two-arm, randomized, multi-dose, double-blind, placebo-controlled,study includes ...
... Md., June 11 EntreMed, Inc.,(Nasdaq: ENMD ... treatment of cancer and inflammatory diseases, today,announced the ... of 2-,methoxyestradiol (2ME2). The patent grants EntreMed composition-of-matter,and ... for analogs,of 2ME2 in oncology and a broad ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 3
(Date:4/22/2014)... The risk of pregnancy among women using a ... more than 10 times greater over a 10-year period ... study by researchers at Yale University and UC Davis ... medical journal Contraception , the study found the ... marketed under the brand name Essure. , "This ...
(Date:4/22/2014)... release is available in German . ... important intracellular signaling molecules, but their mode of action ... of cellular function and behavior, while at high concentrations ... and DNA. To analyze how redox signaling unfolds in ... microscopy technique has been developed jointly by the teams ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated ... national survey by researchers at the University of Michigan ... under the age of 18 at home, and adults ... than other adults to support universal coverage of birth ... the Journal of the American Medical Association ...
(Date:4/22/2014)... has been approved since November 2013 for the prevention ... In an early benefit assessment pursuant to the "Act ... (AMNOG), the German Institute for Quality and Efficiency in ... offers an added benefit over the appropriate comparator therapy. ... of turoctocog alfa is not proven. As no relevant ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
Breaking Medicine News(10 mins):Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3
... of a multi-faceted transcriptional complex to control of ... stem cells. Two separate studies, published by Cell ... Cell, provide insight into novel subunits associated with ... a previously undescribed chromatin function that is required ...
... M.D., Will Lead One of the Nation,s Largest ... Electrophysiology Programs, ... and Director of Cardiac Electrophysiology at,Washington University in St. Louis, has ... Institute., "We are pleased to have such an established leader ...
... largest,provider of business services to orthodontic and dental ... and Atlanta, Georgia to,better serve the company,s practices ... confirm our operating principle that the,heart of our ... in the,hundreds of practices we serve each day," ...
... 11% of international disease burden , , THURSDAY, Jan. 17 ... childhood malnutrition accounts for more than one-third of childhood ... researchers report. , "The key messages here are that ... reform is needed," lead researcher Dr. Robert Black, a ...
... adopt the World Health Organization (WHO) standard on fine particulate ... premature deaths, concludes research in the Journal of Epidemiology and ... levels of fine particulate matter pollution (PM2.5) at 20 g/m ... by the US Environmental Protection Agency is 15 g/m ...
... London, New Delhi and Singapore (January 17, 2008) ... looks set to continue its successful growth in ... partnership with the International Union for Health Promotion ... Promotion & Education. , Published quarterly, Promotion and ...
Cached Medicine News:Health News:Cancer stem cell marker also drives transcription in normal cells 2Health News:Cancer stem cell marker also drives transcription in normal cells 3Health News:Cleveland Clinic Recruits World Renowned Heart Rhythm Specialist to Direct Electrophysiology 2Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 3Health News:Europe should adopt WHO recommendations for particulate matter cuts 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: